SAVA
NASDAQ
Cassava Sciences, Inc. - Common Stock
Healthcare
· Pharmaceuticals
$1.73
▲ +$0.01
(+0.58%)
Vol 301K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$95.6M
ROE
-95.8%
Margin
76.7%
D/E
0.00
Beta
-0.66
52W
$1–$5
Price Chart
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -93.3% | -46.3% | -93.3% | -93.3% | -95.8% | -95.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | 76.7% | 76.7% | 76.7% | 76.7% | 76.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 2.43 | 9.08 | 2.43 | 2.43 | 2.27 | 2.27 |
Key Ratios
ROA (TTM)
-75.3%
P/S (TTM)
2.33
P/B
0.8
EPS (TTM)
$-2.20
CF/Share
$-2.26
52W High
$4.98
52W Low
$1.15
$1.15
52-Week Range
$4.98
How does SAVA compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
SAVA valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
2.3
▼
53%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
0.8
▼
63%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
SAVA profitability vs Pharmaceuticals peers
ROE
-95.8%
▼
77%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
76.7%
▲
262%
above
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-75.3%
▼
101%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
SAVA financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
2.3
▼
33%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
-0.7
▼
170%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
SAVA fundamentals radar
SAVA
Peer median
Industry
SAVA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio